OPKO Health Second Quarter 2025 Earnings: Misses Expectations

OPKO Health (NASDAQ:OPK) Second Quarter 2025 Results

Key Financial Results

• Revenue: US$156.8m (down 14% from 2Q 2024).
• Net loss: US$148.4m (loss widened by US$138.1m from 2Q 2024).
• US$0.19 loss per share (further deteriorated from US$0.015 loss in 2Q 2024).

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

All figures shown in the chart above are for the trailing 12 month (TTM) period

OPKO Health Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 5.4%. Earnings per share (EPS) also missed analyst estimates by 68%.

Looking ahead, revenue is forecast to grow 8.6% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Healthcare industry in the US.

Performance of the American Healthcare industry.

The company's shares are down 12% from a week ago.

Risk Analysis

It is worth noting though that we have found 1 warning sign for OPKO Health that you need to take into consideration.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.